182 related articles for article (PubMed ID: 35212920)
21.
van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
[No Abstract] [Full Text] [Related]
22. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.
Laurie SA; Ho AL; Fury MG; Sherman E; Pfister DG
Lancet Oncol; 2011 Aug; 12(8):815-24. PubMed ID: 21147032
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
[TBL] [Abstract][Full Text] [Related]
24. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
25. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.
Chae YK; Chung SY; Davis AA; Carneiro BA; Chandra S; Kaplan J; Kalyan A; Giles FJ
Oncotarget; 2015 Nov; 6(35):37117-34. PubMed ID: 26359351
[TBL] [Abstract][Full Text] [Related]
26. Dominant cell type analysis predicts head and neck adenoid cystic carcinoma outcomes.
Xuan L; Yuan J; Zhang H; Zhang Y; Liu H
Ann Diagn Pathol; 2022 Feb; 56():151867. PubMed ID: 34826781
[TBL] [Abstract][Full Text] [Related]
27. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R; Swiecicki PL; Zandberg DP; Baiocchi RA; Wesolowski R; Rodriguez CP; McKean M; Kang H; Monga V; Nath R; Palmisiano N; Babbar N; Sun W; Hanna GJ
Oral Oncol; 2024 Feb; 149():106634. PubMed ID: 38118249
[TBL] [Abstract][Full Text] [Related]
28. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
[TBL] [Abstract][Full Text] [Related]
29. Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials.
Wagner VP; Ferrarotto R; Vargas PA; Martins MD; Bingle CD; Bingle L
Crit Rev Oncol Hematol; 2023 Jan; 181():103886. PubMed ID: 36427771
[TBL] [Abstract][Full Text] [Related]
30. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients.
Friedrich RE; Bleckmann V
Anticancer Res; 2003; 23(2A):931-40. PubMed ID: 12820326
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.
Tchekmedyian V; Sherman EJ; Dunn L; Tran C; Baxi S; Katabi N; Antonescu CR; Ostrovnaya I; Haque SS; Pfister DG; Ho AL
J Clin Oncol; 2019 Jun; 37(18):1529-1537. PubMed ID: 30939095
[TBL] [Abstract][Full Text] [Related]
32. Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.
Ganly I; Amit M; Kou L; Palmer FL; Migliacci J; Katabi N; Yu C; Kattan MW; Binenbaum Y; Sharma K; Naomi R; Abib A; Miles B; Yang X; Lei D; Bjoerndal K; Godballe C; Mücke T; Wolff KD; Fliss D; Eckardt AM; Chiara C; Sesenna E; Ali S; Czerwonka L; Goldstein DP; Gil Z; Patel SG
Eur J Cancer; 2015 Dec; 51(18):2768-76. PubMed ID: 26602017
[TBL] [Abstract][Full Text] [Related]
33. Management of adenoid cystic carcinoma of the head and neck: a single-institute study with over 25-year follow-up.
Ishida E; Ogawa T; Rokugo M; Ishikawa T; Wakamori S; Ohkoshi A; Usubuchi H; Higashi K; Ishii R; Nakanome A; Katori Y
Head Face Med; 2020 Jul; 16(1):14. PubMed ID: 32616049
[TBL] [Abstract][Full Text] [Related]
34. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathologic features and prognosis of adenoid cystic carcinoma of external auditory meatus].
Gou XN; Li J; Wang XC; Liu Y; Qiu XM; Shi HY
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):691-695. PubMed ID: 30220123
[No Abstract] [Full Text] [Related]
36. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
Thierauf J; Ramamurthy N; Jo VY; Robinson H; Frazier RP; Gonzalez J; Pacula M; Dominguez Meneses E; Nose V; Nardi V; Dias-Santagata D; Le LP; Lin DT; Faquin WC; Wirth LJ; Hess J; Iafrate AJ; Lennerz JK
Oncologist; 2019 Oct; 24(10):1356-1367. PubMed ID: 30926674
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study.
Slodkowska E; Xu B; Kos Z; Bane A; Barnard M; Zubovits J; Iyengar P; Faragalla H; Turbin D; Williams P; Barnes PJ; Mulligan AM
Am J Surg Pathol; 2020 Feb; 44(2):214-223. PubMed ID: 31567278
[TBL] [Abstract][Full Text] [Related]
38. Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma.
Xu MJ; Wu TJ; van Zante A; El-Sayed IH; Algazi AP; Ryan WR; Ha PK; Yom SS
J Otolaryngol Head Neck Surg; 2018 Apr; 47(1):28. PubMed ID: 29695289
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review.
Papaspyrou G; Hoch S; Rinaldo A; Rodrigo JP; Takes RP; van Herpen C; Werner JA; Ferlito A
Head Neck; 2011 Jun; 33(6):905-11. PubMed ID: 20652885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
